Lobaplatin Inhibits the Proliferation of Hepatollular Carcinoma Through P53 Apoptosis Axis

Wáng, Ying; Wen-ling, Zheng; Ma, Wei

doi:10.5812/hepatmon.6024

Cited by 7 publications

(7 citation statements)

References 18 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lobaplatin arrests cell cycle in G1, G2 and M phase, and upregulates p53 which stops the proliferation of HCC. 21 , 22 Moreover, lobaplatin has reduced toxicity, better therapeutic index, and higher solubility. 23 …”

Section: Discussionmentioning

confidence: 99%

Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma

Kamran

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

Gelatin sponge particles are commonly used in the conventional transarterial chemoembolization (c-TACE) as an adjuvant embolizing agent for hepatocellular carcinoma (HCC). However, there are few reports regarding the clinical applications of gelatin sponge microparticles (GSMs) as a main embolizing agent in the treatment of HCC. This retrospective study aim to evaluate the efficacy and safety of patients with Barcelona Clinic Liver Cancer (BCLC) stage B HCC treated with intra-arterial injection of 350 to 560 μm GSMs mixed with anticancer agents.Twenty-four patients with unresectable BCLC stage B HCC without any prior treatment underwent transarterial chemoembolization with gelatin sponge microparticles (GSMs-TACE) of diameter 350 to 560 μm mixed with lobaplatin. The mixture was injected into tumor-feeding arteries until the sluggish flow in selective artery. Safety was measured by assessing complication rate, and efficacy was reflected by assessing response to mRECIST therapy and overall survival. The survival rate was calculated using the Kaplan–Meier method.All 24 BCLC stage B HCC patients showed good tolerance to the procedure. The mean follow-up period was 27 months and mean number of TACE treatments per patient was 3.7 sessions (range 1–10) during the follow-up period. Postprocedure complications were mild and treated by symptomatic treatment. Six months and 1 year overall survival rates were 100% and 87.5%, respectively. Overall median survival time was 25 months (95%CI: 21.06–28.95 months).GSMs-TACE is a safe and effective method for BCLC stage B HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma

Kamran

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

show abstract

“…Carboplatin, a chemotherapy drug commonly used for TACE at our institution, induces apoptosis and cell cycle arrest through p53 apoptosis. 40 Tumor cell inhibition will be enhanced when TACE and H101 are used together. In addition, over 80% of patients with HCC in Asia are hepatitis B virus (HBV)-positive 41 and over 90% of patients in this study are HBV-positive.…”

Section: Discussionmentioning

confidence: 99%

Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis

Zhang

Lin

2018

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

BackgroundIn analyzing cancer patient survival data, the problem of competing risks is often ignored. This study used a competing risk approach to evaluate the efficacy of recombinant human type-5 adenovirus (H101) in patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE).MethodsIn this retrospective study, 476 patients were included. The cumulative probabilities of cancer-specific mortalities were analyzed by the Kaplan-Meier (KM) method and a competing risk model. Competing risk regression was used to assess the predictive factors for cumulative cancer-specific mortalities.ResultsTwo hundred thirty-eight HCC patients received combination TACE and H101 therapy, and another 238 HCC patients received TACE therapy alone. For patients in the TACE with H101 group, estimated 1-, 2-, and 3-year overall survival (OS) rates were 61.0, 40.0, and 31.5%, respectively, while for patients in the TACE group, the estimated 1-, 2-, and 3-year OS rates were 55.0, 33.4, and 22.3%, respectively. The 1-, 2-, and 3-year cancer-specific mortality rates for patients in the TACE with H101 group vs. the TACE group were 37.3 vs. 42.0%, 55.7 vs. 63.5%, and 61.9 vs. 74.7%, respectively. Multivariate competing risk analysis established that a combination of TACE and H101 therapy was an independent factor in decreasing cancer-specific mortality.ConclusionsCompared with TACE therapy, patients who were diagnosed with unresectable HCC treated with combined TACE and H101 therapy had increased OS and decreased cancer-specific mortality. The survival benefit was more obvious in patients with elevated AFP, absence of metastasis, single tumor, enlarged tumor, and HBsAg-positivity.

show abstract

“…In both groups, lobaplatin was injected into tumor lesions through the hepatic artery. This drug inhibited the proliferation of human HCC cells mostly by activating apoptosis and cell cycle arrest through the p 53 apoptosis axis . Wu et al .…”

Section: Discussionmentioning

confidence: 99%

“…This drug inhibited the proliferation of human HCC cells mostly by activating apoptosis and cell cycle arrest through the p53 apoptosis axis. 33 Wu et al found that p53 upregulation was related to E2F1/Rb in lobaplatin-treated HCC cells, 34 and E2F1 is a transcription factor that plays an important role in regulating cell cycle progression and programmed cell death. 34 Therefore, rAd-p53 injection may improve the efficacy of lobaplatin because p53 gene is mutated or lost in most HCC cells.…”

Section: Discussionmentioning

confidence: 99%

p53 gene therapy‐based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study

Shen

Liu

et al. 2015

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Lobaplatin Inhibits the Proliferation of Hepatollular Carcinoma Through P53 Apoptosis Axis

Cited by 7 publications

References 18 publications

Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma

Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma

Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis

p53 gene therapy‐based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study

Contact Info

Product

Resources

About